IVBX.F Aperçu des actions Innovent Biologics, Inc. est une société biopharmaceutique qui développe et commercialise des anticorps monoclonaux et d'autres médicaments dans les domaines de l'oncologie, de l'ophtalmologie, des maladies auto-immunes, cardiovasculaires et métaboliques en République populaire de Chine. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Innovent Biologics, Inc. Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Innovent Biologics Historique des cours de bourse Prix actuel de l'action HK$4.58 Plus haut sur 52 semaines HK$6.40 Plus bas sur 52 semaines HK$3.83 Bêta 0.24 Variation sur 1 mois -5.57% Variation sur 3 mois n/a Variation sur 1 an -8.95% Variation sur 3 ans -29.10% Variation sur 5 ans 34.71% Évolution depuis l'introduction en bourse 45.20%
Nouvelles et mises à jour récentes
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26
Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Sep 18
Innovent Biologics, Inc. Announces Change in Composition of Board Committees Aug 30 Voir plus de mises à jour
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26
Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Sep 18
Innovent Biologics, Inc. Announces Change in Composition of Board Committees Aug 30
Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China Aug 22
The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert Aug 21
Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) Aug 02
the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc Aug 01
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions Jun 25
Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA May 29
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 May 23
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer May 08
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer Apr 30
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application Apr 02
Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024 Mar 21
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 Mar 07
Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer Mar 06
Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 01
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease Feb 20
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee Feb 10
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China Feb 07 Innovent Biologics, Inc. Announces Chief Financial Officer Changes Feb 05
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints Jan 09
China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib Dec 19
Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications Dec 18
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Dec 08
Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351 Nov 25
Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib Nov 23
Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care Nov 22
The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients Nov 18
Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity Oct 30
Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor) Sep 29 Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 20
National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo Aug 17
Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023 Aug 08 IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting Jun 12 Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC Jun 05
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Jun 03
Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint May 11
Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy May 10
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Feb 16
Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy Feb 15
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications Jan 19
Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Jan 10
Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib Jan 06 Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Dec 05
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity Nov 15
Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022 Nov 07
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors Oct 31
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 19
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 17 Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma
Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study Sep 08
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 07
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 06
Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies Aug 24
Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) Aug 18
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint Aug 11
Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema Aug 08 Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V. Aug 05
Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy Aug 01
Innovent Biologics, Inc. Announces CDE Accepts and Grants Priority Review Designation to New Drug Application Jul 20
Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint Jul 19
Innovent Biologics, Inc. Announces First Patient Dosed in a Phase 2 Clinical Study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis Jul 05
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications Jun 29
Innovent Biologics, Inc. and Eli Lilly and Company Jointly Announces Approval of TYVYT by China NMPA in Combination with Chemotherapy as First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Jun 28
The National Medical Products Administration Approves the Supplemental New Drug Application for TYVYT® (Sintilimab Injection) in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Jun 25 Innovent and Lilly Jointly Announce the Approval of TYVYT (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody) Innovent Biologics, Inc. and IASO Biotherapeutics Presents Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Innovent Biologics, Inc. Announces Phase 2 Study of Mazdutide(Ibi362 in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints Jun 08
AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022 Jun 07 Innovent Biologics, Inc. Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor)
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma Jun 03
Innovent Appoints Gary Zieziula as Independent Non-Executive Director Jun 01
Innovent to Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology Annual Meeting May 16 Rendement pour les actionnaires IVBX.F US Biotechs US Marché 7D -5.7% -3.6% -2.4% 1Y -8.9% -2.6% 23.4%
Voir le rapport complet des actionnaires
Rendement vs Industrie: IVBX.F a sous-performé le secteur US Biotechs qui a rapporté -2.6 % au cours de l'année écoulée.
Rendement vs marché: IVBX.F a sous-performé le marché US qui a rapporté 23.4 % au cours de l'année écoulée.
Volatilité des prix Is IVBX.F's price volatile compared to industry and market? IVBX.F volatility IVBX.F Average Weekly Movement n/a Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Cours de l'action stable: Le cours de l'action de IVBX.F a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de IVBX.F au cours de l'année écoulée.
À propos de l'entreprise Innovent Biologics, Inc. est une société biopharmaceutique qui développe et commercialise des anticorps monoclonaux et d'autres médicaments dans les domaines de l'oncologie, de l'ophtalmologie, des maladies auto-immunes, cardiovasculaires et métaboliques en République populaire de Chine. Elle propose Tyvyt, un anticorps monoclonal anti-PD-1 humain ; BYVASDA, un anticorps monoclonal anti-VEGF entièrement humain ; HALPRYZA, un anticorps monoclonal chimérique recombinant murin/humain anti-CD20 ; SULINNO, un anticorps monoclonal anti-TNF-a entièrement humain ; Pemazyre, un inhibiteur sélectif du FGFR ; Olverembatinib, une nouvelle TK BCR-ABL ; Cyramza, un antagoniste du récepteur 2 du VEGF ; et Retsevmo, un inhibiteur sélectif et puissant de la kinase RET. La société développe également IBI-326, une thérapie cellulaire CAR BCMA entièrement humaine ; IBI-376, un inhibiteur oral de PI3Kd ; IBI-351, un inhibiteur de KRASG12C ; IBI-344, un inhibiteur de tyrosine kinase répresseur de silençage 1/TRK ; IBI-126, un ADC ciblant CEACAM5 ; IBI-306, un nouvel anticorps monoclonal anti-protéine convertase subtilisine/kexine de type 9 ; IBI-362, un agoniste double du récepteur du peptide-1 de type glucagon et du récepteur du glucagon ; et IBI-112, un nouvel anti-IL-23 à longue durée d'action.
Afficher plus Innovent Biologics, Inc. Résumé des fondamentaux Comment les bénéfices et les revenus de Innovent Biologics se comparent-ils à sa capitalisation boursière ? IVBX.F statistiques fondamentales Capitalisation boursière US$7.41b Bénéfices(TTM) -US$175.63m Recettes(TTM ) US$1.02b
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) IVBX.F compte de résultat (TTM ) Recettes CN¥7.46b Coût des recettes CN¥2.12b Marge brute CN¥5.34b Autres dépenses CN¥6.62b Les revenus -CN¥1.28b
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -0.78 Marge brute 71.58% Marge bénéficiaire nette -17.18% Ratio dettes/capitaux propres 25.8%
Quelles ont été les performances à long terme de IVBX.F?
Voir les performances historiques et les comparaisons
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2024/12/22 05:14 Cours de l'action en fin de journée 2024/12/20 00:00 Les revenus 2024/06/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Innovent Biologics, Inc. est couverte par 53 analystes. 29 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd. Bo Li BofA Global Research
Afficher 50 plus d'analystes 
